Status:
RECRUITING
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Monkeypox
Eligibility:
All Genders
18+ years
Brief Summary
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
Detailed Description
Mpox is an endemic zoonosis in Africa, caused by the MPXV virus of which there are two clades: I (former Congo Basin) and II (former West Africa). Since 2022, clade II has emerged globally via sexual ...
Eligibility Criteria
Inclusion
- Men aged over 18 years
- Have received two doses of MVA-BN vaccine as an initial schedule
- Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
- Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
- Covered by social security (excluding AME)
Exclusion
- History of mpox (virologically confirmed)
- Be under guardianship or curatorship
- Be subject to a judicial protection measure
- Have a contraindication to vaccination against mpox
Key Trial Info
Start Date :
May 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06885853
Start Date
May 7 2025
End Date
November 1 2027
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIC 1417Cochin-Pasteur
Paris, Paris, France, 75679